BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33634856)

  • 21. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
    Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
    J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].
    SHAQ Multicenter Study Group of Children's Acute Lymphoblastic Leukemia Research
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):495-501. PubMed ID: 24267129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.
    Uckun FM; Gaynon PS; Stram DO; Sensel MG; Sarquis MB; Lazarus KH; Willoughby M
    Clin Cancer Res; 1999 Sep; 5(9):2415-20. PubMed ID: 10499612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
    Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
    Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
    Giebel S; Krawczyk-Kuliś M; Adamczyk-Cioch M; Czyz A; Lech-Marańda E; Piatkowska-Jakubas B; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
    Pol Arch Med Wewn; 2008 Jun; 118(6):356-61. PubMed ID: 18619191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
    Wacker P; Land VJ; Camitta BM; Kurtzberg J; Pullen J; Harris MB; Shuster JJ;
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):627-32. PubMed ID: 17805038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the Childrens Cancer Group.
    Finklestein JZ; Miller DR; Feusner J; Stram DO; Baum E; Shina DC; Johnson DG; Gyepes MT; Hammond GD
    Cancer; 1994 Jan; 73(1):219-23. PubMed ID: 8275428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
    Strullu M; Corradini N; Audrain M; Orsonneau JL; Bouige D; Thomare P; Vermot-Desroches C; Mansuy A; Legrand A; Rozé JC; Mohty M; Méchinaud F
    Leuk Lymphoma; 2010 Aug; 51(8):1464-72. PubMed ID: 20545581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
    Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
    J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
    Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
    Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
    J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
    Kawedia JD; Liu C; Pei D; Cheng C; Fernandez CA; Howard SC; Campana D; Panetta JC; Bowman WP; Evans WE; Pui CH; Relling MV
    Blood; 2012 Feb; 119(7):1658-64. PubMed ID: 22117041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group Study.
    van Eys J; Berry D; Crist W; Doering E; Fernbach D; Pullen J; Shuster J; Wharam M
    Cancer; 1989 Jan; 63(1):23-9. PubMed ID: 2910421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
    Fernandez CA; Stewart E; Panetta JC; Wilkinson MR; Morrison AR; Finkelman FD; Sandlund JT; Pui CH; Jeha S; Relling MV; Campbell PK
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1307-13. PubMed ID: 24771103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.
    Kutszegi N; Semsei ÁF; Gézsi A; Sági JC; Nagy V; Csordás K; Jakab Z; Lautner-Csorba O; Gábor KM; Kovács GT; Erdélyi DJ; Szalai C
    PLoS One; 2015; 10(10):e0140136. PubMed ID: 26457809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
    Vyas C; Jain S; Kapoor G; Mehta A; Takkar Chugh P
    Pediatr Hematol Oncol; 2018; 35(5-6):331-340. PubMed ID: 30488741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testicular relapse in childhood acute lymphoblastic leukemia: the challenges and lessons.
    Kulkarni KP; Marwaha RK; Trehan A; Bansal D
    Indian J Cancer; 2010; 47(2):134-8. PubMed ID: 20448374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.